TAR DNA-binding protein 43 and pathological subtype of Alzheimer's disease impact clinical features

Annals of Neurology

Volumn 78, Issue 5, 2015, Pages 697-709

  Josephs, Keith A ^a   Whitwell, Jennifer L ^a   Tosakulwong, Nirubol ^a   Weigand, Stephen D ^a   Murray, Melissa E ^b   Liesinger, Amanda M ^b   Petrucelli, Leonard ^c   Senjem, Matthew L ^a   Ivnik, Robert J ^a   Parisi, Joseph E ^a   Petersen, Ronald C ^a   Dickson, Dennis W ^b  

^a MAYO CLINIC   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

^c MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; TAR DNA BINDING PROTEIN; DNA BINDING PROTEIN; TARDBP PROTEIN, HUMAN;

AGED; ALZHEIMER DISEASE; AMNESTIC ALZHEIMER DISEASE; AMYGDALOID NUCLEUS; ARTICLE; ATYPICAL ALZHEIMER DISEASE; BASAL GANGLION; BRAIN REGION; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE DURATION; DSM-IV; FEMALE; GENOTYPE; HIPPOCAMPAL CA1 REGION; HIPPOCAMPUS; HUMAN; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; MEDIAL FRONTAL CORTEX; MINI MENTAL STATE EXAMINATION; NEUROFIBRILLARY TANGLE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROSPECTIVE STUDY; SUBICULUM; TEMPORAL CORTEX; TIME OF DEATH; CLASSIFICATION; COGNITION; DISEASE EXACERBATION; GENE FREQUENCY; GENETICS; LIMBIC SYSTEM; MEMORY DISORDER; MIDDLE AGED; NEOCORTEX; NEUROPSYCHOLOGICAL TEST; ONSET AGE; PATHOLOGY; PSYCHOMOTOR PERFORMANCE; TDP 43 PROTEINOPATHY; VERY ELDERLY;

AGE OF ONSET; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; COGNITION; DISEASE PROGRESSION; DNA-BINDING PROTEINS; FEMALE; GENE FREQUENCY; HIPPOCAMPUS; HUMANS; LIMBIC SYSTEM; MALE; MEMORY DISORDERS; MIDDLE AGED; NEOCORTEX; NEUROFIBRILLARY TANGLES; NEUROPSYCHOLOGICAL TESTS; PSYCHOMOTOR PERFORMANCE; TDP-43 PROTEINOPATHIES;

EID: 84945477559     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.24493     Document Type: Article

References (37)

1. Braak H, Braak E,. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991; 82: 239-259.
2. Murray ME, Graff-Radford NR, Ross OA, et al., Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics: a retrospective study. Lancet Neurol 2011; 10: 785-796.
3. Whitwell JL, Dickson DW, Murray ME, et al., Neuroimaging correlates of pathologically defined subtypes of Alzheimer's disease: a case-control study. Lancet Neurol 2012; 11: 868-877.
4. Amador-Ortiz C, Lin WL, Ahmed Z, et al., TDP-43 immunoreactivity in hippocampal sclerosis and Alzheimer's disease. Ann Neurol 2007; 61: 435-445.
5. Josephs KA, Murray ME, Whitwell JL, et al., Staging TDP-43 pathology in Alzheimer's disease. Acta Neuropathol 2014; 127: 441-450.
6. Josephs KA, Whitwell JL, Knopman DS, et al., Abnormal TDP-43 immunoreactivity in AD modifies clinicopathologic and radiologic phenotype. Neurology 2008; 70 (19 pt 2): 1850-1857.
7. Arai T, Mackenzie IR, Hasegawa M, et al., Phosphorylated TDP-43 in Alzheimer's disease and dementia with Lewy bodies. Acta Neuropathol 2009; 117: 125-136.
8. Davidson YS, Raby S, Foulds PG, et al., TDP-43 pathological changes in early onset familial and sporadic Alzheimer's disease, late onset Alzheimer's disease and Down's syndrome: association with age, hippocampal sclerosis and clinical phenotype. Acta Neuropathol 2011; 122: 703-713.
9. Uryu K, Nakashima-Yasuda H, Forman MS, et al., Concomitant TAR-DNA-binding protein 43 pathology is present in Alzheimer disease and corticobasal degeneration but not in other tauopathies. J Neuropathol Exp Neurol 2008; 67: 555-564.
10. Kadokura A, Yamazaki T, Lemere CA, Takatama M, Okamoto K,. Regional distribution of TDP-43 inclusions in Alzheimer disease (AD) brains: their relation to AD common pathology. Neuropathology 2009; 29: 566-573.
11. Josephs KA, Whitwell JL, Weigand SD, et al., TDP-43 is a key player in the clinical features associated with Alzheimer's disease. Acta Neuropathol 2014; 127: 811-824.
12. Hu WT, Josephs KA, Knopman DS, et al., Temporal lobar predominance of TDP-43 neuronal cytoplasmic inclusions in Alzheimer disease. Acta Neuropathol 2008; 116: 215-220.
13. Wilson RS, Yu L, Trojanowski JQ, et al., TDP-43 pathology, cognitive decline, and dementia in old age. JAMA Neurol 2013; 70: 1418-1424.
14. American Psychiatric Association. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders, 4th ed, text rev. Washington, DC: American Psychiatric Association; 2000.
15. Mirra SS, Heyman A, McKeel D, et al., The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991; 41: 479-486.
16. Dubois B, Feldman HH, Jacova C, et al., Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurol 2014; 13: 614-629.
17. Zhang YJ, Xu YF, Cook C, et al., Aberrant cleavage of TDP-43 enhances aggregation and cellular toxicity. Proc Natl Acad Sci U S A 2009; 106: 7607-7612.
18. Jack CR, Jr., Lowe VJ, Senjem ML, et al., 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain 2008; 131 (pt 3): 665-680.
19. Tzourio-Mazoyer N, Landeau B, Papathanassiou D, et al., Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage 2002; 15: 273-289.
20. Whitwell JL, Jack CR, Jr., Przybelski SA, et al., Temporoparietal atrophy: a marker of AD pathology independent of clinical diagnosis. Neurobiol Aging 2011; 32: 1531-1541.
21. Whitwell JL, Crum WR, Watt HC, Fox NC,. Normalization of cerebral volumes by use of intracranial volume: implications for longitudinal quantitative MR imaging. AJNR Am J Neuroradiol 2001; 22: 1483-1489.
22. Folstein MF, Folstein SE, McHugh PR,. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-198.
23. Morris JC,. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993; 43: 2412-2414.
24. Wechsler D,. Wechsler Memory Scale-Revised. New York: Psychological Corporation; 1987.
25. Kaplan E, Goodglass H, Weintraubb S,. The Boston Namiing Test. Philadelphia, PA: Lea & Febiger; 1983.
26. Benton AL, Hamsher K,. Manual. Multilingual Aphasia Examination. Iowa City, IA: University of Iowa; 1989.
27. Wechsler D,. Wechsler Adult Intelligence Scale-III. New York: Psychological Corporation; 1997.
28. Cohen J,. Statistical Power Analysis for the Behavioral Sciences, 2nd ed. Hillsdale, NJ: Erlbaum; 1988.
29. Sullivan SG, Greenland S,. Bayesian regression in SAS software. Int J Epidemiol 2013; 42: 308-317.
30. Agresti A, Coull BA,. Approximate is better than "exact" for interval estimation of binomial proportions. Am Stat 1998; 52: 119-126.
31. Bigio EH, Mishra M, Hatanpaa KJ, et al., TDP-43 pathology in primary progressive aphasia and frontotemporal dementia with pathologic Alzheimer disease. Acta Neuropathol 2010; 120: 43-54.
32. Josephs KA, Whitwell JL, Duffy JR, et al., Progressive aphasia secondary to Alzheimer disease vs FTLD pathology. Neurology 2008; 70: 25-34.
33. Murray ME, Cannon A, Graff-Radford NR, et al., Differential clinicopathologic and genetic features of late-onset amnestic dementias. Acta Neuropathol 2014; 128: 411-421.
34. Nelson PT, Schmitt FA, Lin Y, et al., Hippocampal sclerosis in advanced age: clinical and pathological features. Brain 2011; 134 (pt 5): 1506-1518.
35. Nag S, Yu L, Capuano AW, et al., Hippocampal sclerosis and TDP-43 pathology in aging and Alzheimer's disease. Ann Neurol 2015 Feb 23. doi: 10.1002/ana.24388.
36. Josephs KA, Nelson PT,. Unlocking the mysteries of TDP-43. Neurology 2015; 84: 870-871.
37. Jung Y, Dickson DW, Murray ME, et al., TDP-43 in Alzheimer's disease is not associated with clinical FTLD or Parkinsonism. J Neurol 2014; 261: 1344-1348.